Fonds Vives II (University of Louvain, UCL)
investment firm
About
Fonds Vives II (University of Louvain, UCL)
Highlights
Details
- Operating Status
- Active
Investments
Number of Investments
Number of Lead Investments
5
0
Fonds Vives II (University of Louvain, UCL) has made 5 investments. Their most recent investment was on
Dec 15, 2021, when Sunrise raised €6.50M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 15, 2021
Sunrise
|
Seed | €6.50M | Health Care | — |
|
May 28, 2020
Virovet
|
Series B | €6M | Biotechnology | — |
|
Jun 20, 2018
ITeos Therapeutics
|
Series B | $75M | Biotechnology | — |
|
Apr 27, 2018
A-Mansia Biotech
|
Series A | €13M | Biopharma | — |
|
May 3, 2012
ITeos Therapeutics
|
Series A | €9M | Biotechnology | — |
Exits
Fonds Vives II (University of Louvain, UCL) has had 1 exits. Fonds Vives II (University of Louvain, UCL) most notable exits include ITeos Therapeutics
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Jul 23, 2020 | ITeos Therapeutics | IPO | Biotechnology | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
